Whalen Wealth Management Inc. Takes Position in Insmed, Inc. (NASDAQ:INSM)

Whalen Wealth Management Inc. acquired a new position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 2,845 shares of the biopharmaceutical company's stock, valued at approximately $217,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in INSM. National Bank of Canada FI increased its holdings in shares of Insmed by 9.7% during the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 147 shares in the last quarter. Snowden Capital Advisors LLC lifted its position in Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after buying an additional 158 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its position in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 163 shares during the last quarter. M&T Bank Corp grew its stake in shares of Insmed by 5.6% in the 4th quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock valued at $217,000 after buying an additional 166 shares during the period. Finally, Envestnet Portfolio Solutions Inc. increased its stake in Insmed by 3.7% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,314 shares of the biopharmaceutical company's stock worth $436,000 after acquiring an additional 225 shares during the last quarter.

Insmed Trading Up 0.5%

Shares of Insmed stock traded up $0.48 during mid-day trading on Tuesday, hitting $105.90. 4,432,312 shares of the stock were exchanged, compared to its average volume of 2,174,346. The stock has a market capitalization of $20.09 billion, a price-to-earnings ratio of -17.80 and a beta of 0.80. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $107.91. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. The company has a 50-day simple moving average of $76.19 and a 200 day simple moving average of $74.95.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The firm had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. During the same period in the previous year, the firm posted ($1.06) earnings per share. The firm's revenue was up 22.9% on a year-over-year basis. Research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on INSM. Morgan Stanley boosted their target price on Insmed from $90.00 to $102.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. The Goldman Sachs Group boosted their price target on shares of Insmed from $100.00 to $112.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Wells Fargo & Company increased their price objective on Insmed from $107.00 to $119.00 and gave the company an "overweight" rating in a report on Wednesday, June 11th. Royal Bank Of Canada upped their target price on shares of Insmed from $99.00 to $106.00 and gave the company an "outperform" rating in a report on Wednesday, June 11th. Finally, Mizuho raised their target price on shares of Insmed from $96.00 to $110.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Insmed has an average rating of "Moderate Buy" and an average price target of $106.80.

Insider Buying and Selling at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the sale, the insider now owns 89,407 shares in the company, valued at $8,352,401.94. This trade represents a 52.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 6,830 shares of Insmed stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total value of $479,192.80. Following the sale, the chief executive officer now owns 233,924 shares in the company, valued at $16,412,107.84. This represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 430,987 shares of company stock worth $37,320,504 in the last quarter. 3.00% of the stock is owned by insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.